Specific future focus should be maintained not only on suppression of TNF-α signaling as a critical target in the onset of insulin resistance, but also on the putative protective roles of the COX-2-mediated or IL-17A-mediated pathways in metabolic disorders. The gene discussed is IL17A; the disease is Insulin resistance.